Category Archives: Vermont Stem Cells

Nearly one year after Jerika Bolen, the Appleton teenager with an incurable genetic disease, announced her intention to go without a life-sustaining ventilator, experts say her case has had surprisingly minimal impact on the right-to-die debate.

"I fully expected it to continue in the dialogue," said Paul J. Ford, director of the NeuroEthics Program at Cleveland Clinic, about Jerika's story.

Bolen died last September after a lifelong battle with spinal muscular atrophy type 2, which destroys nerves cells in the brain stem and spinal cord that control voluntary muscle activity. She died at Sharon S. Richardson Hospice in Sheboygan Falls, after a final summer that included a prom in her honor in July.

"When I decided, I felt extremely happy and sad at the same time," Jerika told USA TODAY NETWORK-Wisconsin in July 2016. "There were a lot of tears, but then I realized I'm going to be in a better place, and I'm not going to be in this terrible pain."

Jerika's decision drew national attention, including an overwhelming amount of support from well-wishers worldwide. But her story also drew the ire of disability rights groups who attempted to intervene in Jerika's decision to stop treatment.

"It was an exceedingly complicated case," said Arthur Caplan, head of the division of bioethics at New York University's School of Medicine. "(Jerika) was 14, so not quite old enough to be legally able to make her decisions, but old enough that many (medical experts) would say she was old enough to help determine her care."

Jerika was mostly immobile and in chronic pain from SMA. She ranked her pain as a seven on a scale of one to 10 on her best days.

Medications had damaged her body. She had more than 30 visits to operating rooms. She had her spine fused in 2013 and the heads of her femurs removed in 2015.

The day of Jerika's death, Jen Bolen, who declined to be interviewed for this story, told USA TODAY NETWORK-Wisconsin that "no one in their right mind would let someone suffer like she was."

"Suffering is a pretty strong, compelling reason to back away," Caplan said.

Not Dead Yet, a national disability rights group, was one of five disability rights groups that asked authorities to conduct an investigation into Jerika's care.

Diane Coleman, Not Dead Yet's president and CEO, said the groups questioned Jerika's decision to die, as well as the public's response.

"We were trying to be gentle and respectful, but also to say that Jerika had a lot to live for, even if she couldn't yet see that herself," Coleman said.

A letter Not Dead Yet and other disability rights groups wrote in early August 2016 raised questions about Jerika's care and said the teenager was "clearly suicidal." Disability Rights Wisconsin also wrote a letter to Outagamie County child protection authorities.

"For Jerika's case, it really pushes the boundaries between the right to refuse treatment and assisted suicide," Coleman said. "If she had continued using her (ventilator)...things would be different, and she didn't get to get there.

"Almost all of the coverage supported her death. That's what's wrong."

Ford said it's difficult from the outside to understand a person's life and level of suffering.

"(Jerika) went through a lot," Caplan said. "She knows more about that than many people weighing in on what should happen."

Caplan said Jerika's story didn't take on the dimension of Terry Schiavo, a Florida woman who remained in a "persistent" vegetative state for 15 years, or Brittany Maynard, a 29-year-old with brain cancer who relocated to Oregon so she could legally kill herself with medication.

"(Jerika) was saying, 'I've been through so much. I don't want to do this anymore,'" Caplan said. "Which is an important question, but it isn't quite analogous to what happens either when someone requests help in dying or says, 'I don't want to be maintained because I'm so old and so frail that there's no point.' She was in a different situation."

Caplan said Americans are "completely and utterly confused" about right-to-die issues, including how to deal with mental impairment in dying, whether to honor a child's request and even what constitutes death.

"Where views diverge is saying how much suffering is too much to ask someone to bear, and whose responsibility is it to partake in ending a life if it's more suffering than anyone ought to bear," Ford, the Cleveland Clinic ethicist, said.

One of those issues is physician-assisted suicide. Public opinion about the practice remains divided: a 2013 Pew Research Center survey found that 47 percent of Americans approve of laws to allow the practice for the terminally ill, while 49 percent disapprove.

Five states California, Colorado, Oregon, Vermont and Washington and Washington, D.C., have legalized the practice, and Montana recognized it following a state Supreme Court ruling.

Ford said there was "a great energy among states" to continue the legislation for terminally ill adults a year ago.

"Those have sort of taken a backseat, recently," he said.

Earlier this year, Wisconsin State Rep. Sondy Pope introduced legislation, modeled closely after other physician-assisted suicide laws, that would allow terminally ill Wisconsin adults to receive medication to end their lives.

"It's about as restrictive as it could be. ... There are so many safeguards that it's almost impossible to use," Pope said.

Pope, who conceded that the legislation has no immediate chance of becoming law, said she would support legislation to allow a minor who isn't terminal to die with "very, very thoughtful safeguards that include input from loved ones."

"That's way down the road in a case-by-case individual basis ... It doesn't seem right, morally, to say, 'I'm sorry. You're not 18. You have to suffer.'"

___

Information from: Post-Crescent Media, http://www.postcrescent.com

An AP Member Exchange shared by the Post-Crescent.

Originally posted here:
Continuing the debate about right-to-die issues in Appleton - Wichita Eagle

Jerika Bolen, the 14-year-old who made headlines when she decided to stop treatment for Type 2 Spinal Muscular Atrophy, has died.

Jerika Bolen and her mother, Jen, share a moment on the way to a July 2016 prom in Appleton, Wis. Jerika died in September 2016, after she decided to end treatment for an incurable genetic disease.(Photo: Danny Damiani, The (Appleton, Wis.) Post-Crescent)

APPLETON, Wis. Nearly one year after a Wisconsin teen with an incurable genetic disease announced her intention to go without a life-sustaining ventilator, experts say her case has had surprisingly minimal impact on the right-to-die debate.

"I fully expected it to continue in the dialogue," said Paul J. Ford, director of the NeuroEthics Program at Cleveland Clinic, about Jerika Bolen's story.

Jerika, of Appleton, Wis., died last September after a lifelong battle with spinal muscular atrophy type 2, which destroys nerves cells in the brain stem and spinal cord that control voluntary muscle activity. Her death last year came after a final summer that included a prom in her honor in July.

When I decided, I felt extremely happy and sad at the same time, Jerika told USA TODAY NETWORK-Wisconsin in July 2016. There were a lot of tears, but then I realized Im going to be in a better place, and Im not going to be in this terrible pain."

More: Following 'Last Dance' prom, Wisconsin teen Jerika Bolen dies

Jerika's decision drew national attention, including an overwhelming amount of support from well-wishers worldwide. But her story also drew the ire of disability rights groups who attempted to intervene in Jerika's decision to stop treatment.

For Jerika's case, it really pushes the boundaries between the right to refuse treatment and assisted suicide.

"It was an exceedingly complicated case," said Arthur Caplan, head of the division of bioethics at New York Universitys School of Medicine. "(Jerika) was 14, so not quite old enough to be legally able to make her decisions, but old enough that many (medical experts) would say she was old enough to help determine her care."

Jerika was mostly immobile and in chronic pain from spinal muscular atrophy. She ranked her pain as a seven on a scale of one to 10 on her best days.

Medications had damaged her body. She had more than 30 visits to operating rooms. She had her spine fused in 2013 and the heads of her femurs removed in 2015.

The day of Jerika's death, Jen Bolen, who declined to be interviewed for this story, told USA TODAY NETWORK-Wisconsin that "no one in their right mind would let someone suffer like she was.

"Suffering is a pretty strong, compelling reason to back away," Caplan said.

Not Dead Yet, a national disability rights group, was one of five disability rights groups that asked authorities to conduct an investigation into Jerika's care.

Diane Coleman, Not Dead Yet's president and CEO, said the groups questioned Jerika's decision to die, as well as the public's response.

More: Wisconsin teen's battle to stop treatment isnt unique

More: Is Wisconsin teen's decision to die a turning point?

"We were trying to be gentle and respectful, but also to say that Jerika had a lot to live for, even if she couldn't yet see that herself," Coleman said.

(Jerika) was 14, so not quite old enough to be legally able to make her decisions, but old enough that many (medical experts) would say she was old enough to help determine her care.

A letter Not Dead Yet and other disability rights groups wrote in early August 2016 raised questions about Jerika's care and said the teenager was "clearly suicidal." Disability Rights Wisconsin also wrote a letter to Outagamie County, Wis., child protection authorities.

"For Jerika's case, it really pushes the boundaries between the right to refuse treatment and assisted suicide," Coleman said. "If she had continued using her (ventilator) ... things would be different, and she didn't get to get there.

"Almost all of the coverage supported her death. That's what's wrong."

Ford said it's difficult from the outside to understand a person's life and level of suffering.

"(Jerika) went through a lot," Caplan said. "She knows more about that than many people weighing in on what should happen."

Caplan said Jerika's story didn't take on the dimension of Terry Schiavo, a Florida woman who remained in a "persistent" vegetative state for 15 years, or Brittany Maynard, a 29-year-old with brain cancer who relocated to Oregon so she could legally kill herself with medication.

"(Jerika) was saying, 'I've been through so much. I don't want to do this anymore,' " Caplan said. "Which is an important question, but it isn't quite analogous to what happens either when someone requests help in dying or says, 'I don't want to be maintained because I'm so old and so frail that there's no point.' She was in a different situation."

More: Q&A: What you should know about right to die

More: Child neglect claimed in teen's plan to end her own life

Caplan said Americans are "completely and utterly confused" about right-to-die issues, including how to deal with mental impairment in dying, whether to honor a child's request and even what constitutes death.

"Where views diverge is saying how much suffering is too much to ask someone to bear, and whose responsibility is it to partake in ending a life if it's more suffering than anyone ought to bear," Ford, the Cleveland Clinic ethicist, said.

One of those issues is physician-assisted suicide. Public opinion about the practice remains divided: a 2013 Pew Research Center survey found that 47% of Americans approve of laws to allow the practice for the terminally ill, while 49% disapprove.

Five states California, Colorado, Oregon, Vermont and Washington and Washington, D.C., have legalized the practice, and Montana recognized it following a state Supreme Court ruling.

Ford said there was "a great energy among states" to continue the legislation for terminally ill adults a year ago.

More: Teen's plan to die has disability groups seeking intervention

More: More than a thousand people turn out for prom of Wisconsin teen choosing to die

"Those have sort of taken a backseat, recently," he said.

Earlier this year, Wisconsin State Rep. Sondy Pope introduced legislation, modeled closely after other physician-assisted suicide laws, that would allow terminally ill Wisconsin adults to receive medication to end their lives.

Pope, who conceded that the legislation has no immediate chance of becoming law, said she would support legislation to allow a minor who isn't terminal to die with "very, very thoughtful safeguards that include input from loved ones."

"That's way down the road in a case-by-case individual basis ... It doesn't seem right, morally, to say, 'I'm sorry. You're not 18. You have to suffer.' "

Follow Ethan Safran on Twitter:@EthanSafran

More: Girl, 14, with incurable disease makes heartbreaking decision to die

Read or Share this story: https://usat.ly/2xGUAiA

More:
Year after Jerika Bolen's death, debate continues on right-to-die issues - USA TODAY

Mark Blazis

Local mushroom hunting guide Matt Ashmankus and I had collected a big basket full of edible mushrooms from his secret spot in Millbury. We found many colorful,but poisonous amanitas and left them alone. Another time, maybe wed satisfy our curiosity and identify each deadly species just for fun. But this day, we were just thinking about safe and delicious mushrooms for dinner.

Its hard to misidentify either boletes, which have porous undercaps, or russulas, which have gilled undercaps. Ashmankus advises that, Boletes are good for beginners to pick. Its hard to find a poisonous one around here, although there is one very uncommon one with a red stem that shouts out, Leave me alone!

Novice mushroom hunters wishing to avoid nasty,gastro-intestinal symptom-causing-boletes would do well to not pick any fungus with orange or red pores, or that bruise blue.

As you can get deathly sick from eating bad mushrooms, we cautiously examined every specimen we had collected, confirming their identifications in our field guide. Violet gray bolete (Tylopilus plumbeo violaceous); two-colored bolete (Boletus bicolor); lilac-brown bolete (Tylopilus eximius); red-cracked bolete (Boletus chrysenteron); ornate-stalked bolete, and Boletus ornatipes would all be carefully scrutinized before sauteing.

Having checked off our field guides and annotated the date and location of our bolete harvest, we then went to the gilled russulas still in our basket: tacky green russula (Russula aeruginea) and fragile russula (Russula fragiles). It then started pouring, so we rushed to place our baskets in my Denali to keep them dry. Wet mushrooms rot quickly. After all our effort to harvest them, they were too valuable to waste.

As a fellow Lithuanian, I understood Ashmankus passion for mushrooms. Gathering them has been part of our ethnic tradition. I saw that surprising phenomenon when I went to Lithuania the very first year they had won their freedom from the Soviet Union.

Dr. Vytautus Logminas, the author of the only field guide to the birds of Lithuania had invited me to study Lithuanian birds and birdbanding research techniques with him there. I never expected hed take me mushrooming with his family and scientific colleagues on our days off.

On weekends, we ventured all over the countryside, like just about everyone else from the great university city of Vilnius. Doctors, lawyers, scientists, truck drivers just about every professional and level of society in the country seemed to be nature starved and have within them a joy for picking mushrooms along with the blueberries that were concurrently ripening, too. I was able to quickly pick a basket of boletes and chanterelles with them, earning their respect.

Unsurprisingly, Ashmankus local mushrooming hunting classes have attracted a good number of eastern Europeans, including Poles, other Lithuanians, and Russians. But some Italians have joined his group, too. Its good theyre learning from him. While edible mushrooms from other parts of the world can look very much like some of our species, the similarities can be deceptive and even dangerous especially now.

From August on, we have our greatest chances of lots of fungus-stimulating precipitation from southern storms, especially hurricane events. September is consequentlythe state'sworst month for mushroom poisonings.

Back in storm-ravaged 2011 arguably the best mushroom year in over two decades there were 63 reported mushroom poisonings in Maine, Vermont, and New Hampshire; and 45 in Massachusetts and Rhode Island. The more rain, the more mushrooms and the more poisonings.

Some novices who were looking for delicious and safe boletus porcinis confused them with similar-looking poisonous lilac brown boletes. And some who thought they were picking edible chanterelles were actually eating toxin-filled jack-o-lantern fungi.

Eating misidentified mushrooms can lead to diarrhea, excruciating abdominal pain, vomiting, liver damage, and in extreme cases death.

Destroying Angels, (Amanita bisporigera or Amanita virosa); death cap (Amanita phalloides); cleft-footed amanita (Amanita brunnescens); yellow-orange fly agaric (Amanita muscaria); Amanita multisquamosa; deadly galerina (Galerina autumnalis); green-spored lepiota (Chlorphyllum molybdites); and false morel, sometimes called brain fungus (Gyromitra esculenta), are some ofthe area'smore poisonous species that could prove fatal.

The widespread and common death cap kills more people than any other. While it looks like a common store mushroom, smells, and even tastes delicious (its a myth that all poisonous mushrooms taste bad), its amatoxins immediately bind to and disable a vital enzyme necessary for protein formation in our cells, rapidly causing our liver to fail.

Symptoms dont appear for aboutsix hours or more after eating. Initial vomiting and diarrhea could mislead one to think that a stomach flu pathogen was the culprit. But soon after, coma is followed by death.

I remember my own Lithuanian mushroom-picking grandmother, who lived to be 100 after eating countless wild mushrooms both in Europe and Massachusetts, telling me a tragic mushroom story that took place back in the old country when she was a young girl. Her closest girl friend at age 15 was married off by her parents to a much older man who was, according to my grandmother, an abusive drunk. In strictest confidence, the young bride shared only with my grandmother that her husband beat her during his drunken rages to the point that she desperately resorted to killing him with a soup she had laced with poison mushrooms.

Of course, there were no forensic studies back then in that rural area. Partly in light of his old age, his death was attributed to natural causes. Only she, my grandmother, and 80 years later this writer ever knew the true story of his demise.

It has been accurately stated many times that there are no old, bold mushroom hunters. Every mushroom hunter, even the most experienced, must always be 100 percent certain of identifications. That means serious time studying and even taking spore prints. Allowing a harvested mushroom to drop its spores overnight on a white piece of paper can reveal its distinctive color and pattern, thereby providing conclusive identification.

Personally, I still pick only the dozen local species that I know perfectly: chanterelles, morels, king boletes, beefsteak mushrooms, honey mushrooms, chicken-of-the-woods, hen-of-the-woods, oyster mushrooms, the coral mushroom Clavaria cineria, slippery Jack, Suillus granulatus, and a safe edible, easily-identified mushroom that should be emerging right about now the black trumpet chanterelle. Look for that delicious beauty under beech trees, where its mossy, or where theres a slight depression where rain collects. Mushroom hunting authority, Russ Cohen suggests looking for them around vernal pools.

Yes, now is the best time of year to find and eat these wild delicacies, but until youre an expert, your fungal forays should all be under the supervision of a mycologist who can teach you how to fully and safely enjoy every one of them.

Contact Mark Blazis at markblazis@charter.net.

View original post here:
Mark Blazis: Mushroom hunting a delicious endeavor - Worcester Telegram

Shoulder Stem Cell and Platelet TreatmentsVermont Regenerative Medicine2017-08-07T18:22:31+00:00Shoulder Stem Cell Therapy and PRP / Platelet Rich Plasma Procedures for Shoulder & Rotator Cuff Injuries and Arthritis

Regenexx Shoulder Stem Cell Therapy and PRP Procedures for Rotator Cuff Injuries offer the most advanced, non-surgical treatments for people suffering from shoulder arthritis, torn rotator cuff, shoulder bursitis, tendonitis and other common injuries. These minimally invasive procedures offer a viable treatment alternative for individuals considering elective shoulder surgery or shoulder replacement surgery.

The shoulder is an incredibly complex joint, making all types of shoulder surgery difficult, with unpredictable outcomes. Shoulder surgery recovery can require months of painful rehabilitation to help rebuild strength and range of motion in the shoulder joint.

Alternatively, the Regenexx procedures may help heal and alleviate shoulder problems with a same-day stem cell or platelet rich plasma injection procedure. Regenexx patients typically experience little to no down time from the procedure and avoid the wide range of problems that often follow surgery.

This outcome information summarizes the 2014 registry data for shoulders treated with the Regenexx Stem Cell Procedure using the patients own stem cells. It was comprised of a mix of patients with rotator cuff tears, arthritis, labral tears, and instability. Rotator cuff tear patients are doing the best in this group.

View This Shoulder / Rotator Cuff Outcome Data

Stem Cells are in all of us and they are responsible for healing injured bone, ligaments, tendons and tissues. They are the key component behind the Regenexx Procedures. As we get older or injured, we sometimes cannot get enough of these cells into the area in need. The Regenexx Procedures help solve that problem by precisely delivering a high concentration of stem cells and growth factors into the injured area, aiding your bodys ability to heal naturally. Regenexx patients experience little or no down-time from the procedure and typically avoid the long, painful rehabilitation periods to restore joint strength and mobility following invasive surgeries.

If you are suffering from a shoulder injury or degenerative condition like osteoarthritis, you may be a good candidate for these ground-breaking stem cell and blood platelet treatments. Please complete the Procedure Candidate Form below and we will immediately email you more information.

See the original post here:
Shoulder Stem Cell and Platelet Treatments - Vermont ...

August 18, 2017 - By Hazel Jackson

Biolife Solutions Incorporated (NASDAQ:BLFS) had an increase of 7.43% in short interest. BLFSs SI was 245,800 shares in August as released by FINRA. Its up 7.43% from 228,800 shares previously. With 22,800 avg volume, 11 days are for Biolife Solutions Incorporated (NASDAQ:BLFS)s short sellers to cover BLFSs short positions. The SI to Biolife Solutions Incorporateds float is 3.89%. The stock decreased 5.23% or $0.24 on August 18, reaching $4.35. About 168,018 shares traded or 15.97% up from the average. BioLife Solutions Inc (NASDAQ:BLFS) has risen 37.27% since August 18, 2016 and is uptrending. It has outperformed by 20.57% the S&P500.

S Muoio & Company increased Clarcor Inc (CLC) stake by 38.27% reported in 2016Q4 SEC filing. S Muoio & Company acquired 4,000 shares as Clarcor Inc (CLC)s stock 0.00%. The S Muoio & Company holds 14,452 shares with $1.19 million value, up from 10,452 last quarter. Clarcor Inc now has $4.06B valuation. It is 0.00% or $0 reaching $0 per share. It is down 0.00% since August 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 2.33 in 2016 Q4. Its up 0.83, from 1.5 in 2016Q3. It is positive, as 3 investors sold BioLife Solutions Inc shares while 0 reduced holdings. 5 funds opened positions while 2 raised stakes. 267,289 shares or 5.47% less from 282,746 shares in 2016Q3 were reported. Blackrock Fund Advsrs has 0% invested in BioLife Solutions Inc (NASDAQ:BLFS) for 2,526 shares. Community Financial Bank Na stated it has 0% in BioLife Solutions Inc (NASDAQ:BLFS). Deutsche National Bank & Trust Ag reported 1 shares. Retail Bank Of America De holds 0% in BioLife Solutions Inc (NASDAQ:BLFS) or 1 shares. Tower Cap Limited Liability (Trc) invested in 0% or 862 shares. Price T Rowe Assoc Incorporated Md has invested 0% in BioLife Solutions Inc (NASDAQ:BLFS). Citadel Advsrs Ltd Liability Company accumulated 16,710 shares. Creative Planning holds 143 shares. Hudock Group Limited Liability Company reported 43 shares. Pnc Financial Group holds 0% or 10,000 shares in its portfolio. The California-based Wells Fargo & Mn has invested 0% in BioLife Solutions Inc (NASDAQ:BLFS). 2,500 are owned by Ancora Limited Liability Company. Vanguard Gru has invested 0% in BioLife Solutions Inc (NASDAQ:BLFS). Blackrock Institutional Na holds 0% of its portfolio in BioLife Solutions Inc (NASDAQ:BLFS) for 33,039 shares. Perkins holds 10,000 shares or 0.02% of its portfolio.

BioLife Solutions, Inc. is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The company has market cap of $57.54 million. The Companys product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. It currently has negative earnings.

Among 2 analysts covering BioLife Solutions (NASDAQ:BLFS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLife Solutions had 4 analyst reports since June 14, 2017 according to SRatingsIntel. The company was maintained on Friday, August 11 by Maxim Group. The stock of BioLife Solutions Inc (NASDAQ:BLFS) earned Buy rating by Maxim Group on Monday, July 31. The company was upgraded on Wednesday, July 5 by Janney Capital. The stock of BioLife Solutions Inc (NASDAQ:BLFS) has Buy rating given on Wednesday, June 14 by Maxim Group.

Investors sentiment decreased to 0.84 in Q4 2016. Its down 0.29, from 1.13 in 2016Q3. It worsened, as 30 investors sold CLC shares while 92 reduced holdings. 42 funds opened positions while 61 raised stakes. 41.40 million shares or 3.54% less from 42.91 million shares in 2016Q3 were reported. Rhumbline Advisers has invested 0.02% of its portfolio in CLARCOR Inc. (NYSE:CLC). Champlain Prns Limited Co owns 2.01 million shares. Qs Invsts Limited Liability Company owns 0% invested in CLARCOR Inc. (NYSE:CLC) for 6 shares. Tower Rech Capital Lc (Trc) stated it has 0.02% in CLARCOR Inc. (NYSE:CLC). Tcw Grp holds 12,484 shares or 0.01% of its portfolio. Metropolitan Life Ins New York owns 77,248 shares or 0.05% of their US portfolio. Kcg Incorporated holds 0.01% of its portfolio in CLARCOR Inc. (NYSE:CLC) for 5,211 shares. Pillar Pacific Cap Mgmt Limited Liability invested in 0.07% or 5,800 shares. Barclays Public Llc invested 0% of its portfolio in CLARCOR Inc. (NYSE:CLC). Gabelli Funds Ltd Limited Liability Company has invested 0.43% in CLARCOR Inc. (NYSE:CLC). Gardner Lewis Asset Mgmt Limited Partnership holds 0.43% or 67,851 shares. Tru Communications Of Vermont reported 4,389 shares. Swiss Bankshares stated it has 80,200 shares. 7,300 were reported by Weik Invest Services. Teachers Retirement Of The State Of Kentucky accumulated 10,300 shares.

S Muoio & Company decreased Frontier Communications Corp Ser B (NASDAQ:FTR) stake by 500,000 shares to 299,192 valued at $1.01M in 2016Q4. It also reduced Gannett Co Inc stake by 52,523 shares and now owns 47,058 shares. Amc Networks Inc (NASDAQ:AMCX) was reduced too.

Among 4 analysts covering CLARCOR (NYSE:CLC), 0 have Buy rating, 2 Sell and 2 Hold. Therefore 0 are positive. CLARCOR had 8 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of CLARCOR Inc. (NYSE:CLC) earned Hold rating by Zacks on Tuesday, August 18. The stock has Sell rating by Zacks on Wednesday, August 12. The firm has Sell rating by Gabelli given on Friday, December 2. On Monday, August 31 the stock rating was upgraded by Zacks to Sell. Robert W. Baird downgraded CLARCOR Inc. (NYSE:CLC) rating on Friday, September 18. Robert W. Baird has Neutral rating and $53 target. The firm has Sell rating given on Tuesday, September 22 by Zacks. The firm earned Hold rating on Tuesday, September 22 by TheStreet. The stock of CLARCOR Inc. (NYSE:CLC) has Neutral rating given on Friday, September 16 by Robert W. Baird.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Excerpt from:
S Muoio & Company Has Raised Its Clarcor (CLC) Position; Biolife Solutions (BLFS) Shorts Raised By 7.43% - HuronReport

News Release FreshTracks Capital July 12, 2017

Media Contacts: Holly Killary [emailprotected] 802.923.1500

Taylor Osumi [emailprotected] 323-462-6600 FreshTracks Capital Invests in Luxury Organic Skincare Company, Ogee

Burlington, VT (July 11, 2017) FreshTracks Capital announces its investment in Ogee, a Vermont-based company that makes luxury organic skincare and beauty products. This is the fifth company investment from FreshTracks Capitals newly launched investment fund, FreshTracks IV, which opened in December 2016. FreshTracks led the $1 million round of financing for Ogee to provide growth capital and help the company expand its business.

Ogee was founded by Mark Rice, Abbott Stark and Alex Stark, who started Ogee together in 2014, and in 2016 won LaunchVTs business pitch contest. The companys founders spent years in the beauty and fashion industries, building some of the worlds leading brands and products, and decided to focus on developing products that represent their own values, with proven ingredients and effective natural formulations.

FreshTracks Capitals Managing Director, T.J. Whalen, said of the deal, Were thrilled to invest in Ogees growth. Weve worked with the team informally for a couple of years, and we know they have what it takes to be successful in the $120 billion global skincare market. With the Ogee teams proven track record and experience in skincare and fashion, they are well positioned to capitalize on industry trends towards well-differentiated, luxury organic skincare products.

Ogees certified organic skincare products feature innovative and effective ingredients like Organic Jojoba Oil and Edelweiss Flower Plant Stem Cells to reduce wrinkles, instantly moisturize and restore healthy, smooth, and glowing skin. Full of essential oils and antioxidants, Ogees products replenish and hydrate to dramatically improve complexion. Ogees unique formulations are catching the eye of many in the industry, and have been featured in Vogue, Vanity Fair, InStyle, Allure and many other beauty and fashion publications. The brand has also received excellent reception from retailers, and is currently carried by Free People, and in prestige beauty boutiques across the U.S., with many strategic expansion initiatives on the horizon. Learn more at http://www.Ogee.com.

The rest is here:
FreshTracks Capital invests in Ogee - vtdigger.org

The Regenexx Family of Advanced Regenerative Medicine Procedures offer breakthrough, non-surgical treatment options for individuals suffering from joint or bone pain due to degenerative conditions, torn or strained tendons or ligaments or other common joint injuries. Regenexx procedures offer viable alternatives for patients with chronic pain who may be considering surgery.

The list below represents the most commonly treated conditions using Regenexx stem cell or platelet procedures. It is not a complete list, so please contact us or complete the Regenexx Candidate Form if you have questions about whether you or your condition can be treated with these non-surgical procedures.

Regenexx is the only stem cell treatment network to publish this type of analysis of patient stem cell procedure outcome data. The analysis is made possible thanks to the massive numbers that are compiled throughout the years in the Regenexx patient registry, which tracks patient outcomes at regular intervals following all of the stem cell procedures we offer.

Note: This patient outcome data is not part of a controlled trial. Every patient becomes part of a registry to track outcomes and any complications. This data is a compilation of patient input to the Regenexx Patient Registry at regular intervals following their Regenexx Procedure. In addition, none of this data may be reproduced in any way or displayed elsewhere without priorwritten permission from Regenerative Sciences.

This Regenexx bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry.

This Regenexx bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry following treatment for Meniscus Tears.

This data utilizes LEFS (Lower Extremity Functional Scale) data from our knee arthritis patients treated with stem cell injections. Functional questionnaires ask the patients questions such as how well they can walk, run, climb stairs, etc. The improvements following the Regenexx Stem Cell Procedure are highly statistically significant.

This outcome information summarizes the patient registry data for shoulders treated with the Regenexx same day stem cell procedure using the patients own stem cells. It was comprised of a mix of patients with rotator cuff tears, arthritis, labral tears, and instability.

This data was derived from a group of patients with mostly severe thumb arthritis who were injected with their own stem cells. Most of these patients would have been candidates for thumb joint replacement or a surgery where a tendon is coiled up in the joint at the base of the thumb. Both are big surgeries with significant complications.

This data analysis is part of the 2015 download of patient results tracked in our advanced treatment registry. The data shown here is predominantly for ankle patients that have on average moderate to severe arthritis with some also having instability in the ligaments and/or tendinitis/tendon tears. A few small foot joint patients are also included in this data set.

This data compares two groups of patients who received epidural steroids vs. PL-Disc and looks at their results at 3 month and 6 month intervals using a Functional Rating Index (FRI), which measures things like pain as well as the ability to walk, sit, lift, bend, etc.

Regenexx has published more data on stem cell safety in peer reviewed medical research for orthopedic applications than any other group world-wide. This is a report of 1,591 patients and 1,949 procedures treated with the Regenexx Stem Cell Procedure. Based on our analysis of this treatment registry data, the Regenexx Stem Cell Procedure is about as safe as any typical injection procedure, which is consistent with what we see every day in the clinic.

Stem cells and platelet-derived growth factors are in all of us and they are responsible for healing injured bone, cartilage, ligaments, tendons and other tissues. They are the key components behind the Regenexx Procedures. As we get older or injured, we sometimes cannot get enough of these cells into the area to heal. The Regenexx Procedures help solve this problem by precisely delivering a high concentration of stem cells and platelets into the injured area, aiding your bodys ability to heal naturally. Patients experience very little down time and they typically avoid the long, painful rehabilitation periods that often follow surgery to restore joint strength and mobility.

The Regenexx Stem Cell Procedure begins when the doctor thoroughly numbs the back of the hip (PSIS) and takes a small bone marrow sample through a needle, as well as a blood draw from a vein in the arm. The marrow is rich in Mesenchymal Stem Cells, which are responsible for healing damaged tissues. The stems cells are isolated from the marrow sample and platelets are isolated from the blood sample. After preparation, these two components will be reinjected directly into the damaged area of the joint using advanced imaging guidance. This ensures the cells are delivered to the exact location of need.

Platelet Rich Plasma Therapy (PRP) is the 1st realistic step in regenerative medicine treatment for musculoskeletal disease. Specifically utilizing a patients own blood, we are able to inject a high concentration of platelets and growth factors into the area that has been injured helping to enhance and speed the recovery process from both acute and chronic tendon and joint diseases. As part of the Regenexx Network, were able to offer our patients the Regenexx Super Concentrated Platelet Rich Plasma Procedure, the most advanced form of PRP available today. All PRP is not created equal. The Regenexx procedure offers higher platelet concentrations and a much more pure PRP mixture.

Your bodys own stem cells control the process of tissue building in the body. They direct the growth of new tissue. When a joint, tendon, or ligament has been injured to a degree that the normal healing process has stalled or is not working correctly, injecting stem cells into an area of injury can help repair tissue.

Regenerative treatments can help improve pain and functional ability. In mild to moderate cases it may have the ability to repair damaged tissue. In more advanced cases it can still help with pain. This is different than steroid injections which help pain alone.

If you are suffering from a joint injury, joint pain, a non-healing fracture or a degenerative condition like osteoarthritis, you may be a good candidate for these ground-breaking stem cell and blood platelet treatments. Please complete the Procedure Candidate Form below and we will immediately email you more information.

See more here:
Regenexx Stem Cell & Platelet Procedures - Vermont ...

Knee Stem Cell TherapyVermont Regenerative Medicine2016-04-25T13:58:28+00:00 Regenexx Advanced Knee Stem Cell Therapy and Platelet Rich Plasma Procedures for Common Knee Injuries and Knee Osteoarthritis

Regenexx Knee Stem Cell Therapy and Platelet Procedures are breakthrough, non-surgical treatments for people suffering from knee pain due to common injuries to the knee meniscus, ACL or MCL, cartilage, or who are experiencing degenerative conditions, such as osteoarthritis. Traditional options for patients suffering from these conditions include arthroscopic knee surgery to repair ligament tears, or total knee joint replacement. With both surgeries, months of rehab are required, and the patient must be aware of and prepared to take on the risks. As an alternative, the Regenexx Stem Cell Procedure, or Regenexx Super Concentrated Platelet Rich Plasma Procedure may help alleviate knee pain and the conditions that cause it with a simple office injection procedure.

[dk-outcome slug=knee knee-meniscus knee-pain-and-function safety intro=show ]

[dk-network-graphic img=regenexx-difference-infographic width=100% ]

Stem Cells are in all of us and they are responsible for healing injured bone, ligaments, tendons and tissues. They are the key component behind the Regenexx Procedures. As we get older or injured, we sometimes cannot get enough of these cells into the area in need. The Regenexx Procedures help solve that problem by precisely delivering a high concentration of stem cells and growth factors into the injured area, aiding your bodys ability to heal naturally. Patients typically avoid the long, painful rehabilitation periods to restore joint strength and mobility following surgery. Regenexx patients are usually encouraged to walk the same day, and most experience little or no down-time from the procedure.

If you are suffering from pain due to an injury, degenerative condition, or prior surgery, you may be a good candidate for this ground-breaking treatment. Please complete the Candidate Form below and you will immediately receive more detailed information on the procedure, along with next steps in determining whether this procedure is right for you. Completion of this form does not constitute a patient/physician relationship.

Read this article:
Knee Stem Cell Therapy - Vermont Regenerative Medicine

ORTHOPAEDIC MEDICINE SPECIALTIES FOR PAIN TREATMENT Orthopaedic medicine is a specialty devoted to the evaluation, diagnosis and non-operative treatment for pain caused by musculoskeletal diseases to aid in pain management. Diagnostic modalities include a comprehensive history, a detailed and specific physical examination, radiologic evaluations and local anesthetic blocks for pain treatment. Therapeutic modalities for pain management encompass manipulations, corticosteroid or proliferant injections with and without fluoroscopic guidance, therapeutic exercise and use of pharmaceutical, nutriceutical, herbal and/or homeopathic based pain treatment.

The evolution began in 1741 when Nicholas Andre, at that time a Professor of Medicine at the University of Paris, coined the word orthopaedic. He published a book with the same title. The etymology of orthopaedic is based on two greek roots: orthos and paedia which translate to straight and rearing of children respectively. His illustration of a staff that is used to straighten a growing tree is known world wide.

For more than two centuries orthopaedists were physicians or surgeons concerned with musculoskeletal deformities: scoliosis, infections of bones and joints, poliomyelitis and congenital defects such as Erbs palsy, clubfoot and hip dislocations. Until the 20th century most orthopaedic treatments were manipulations and mechanical support with braces and plaster casts.

The American Orthopaedic Association was founded in 1887. The separation of orthopaedic surgery from general surgery took place in 1934 with the establishment of a separate board. According to the late Dr. Cyriax, orthopaedic medicine was established in 1929. The American Association of Orthopaedic Medicine was founded in 1982.

The accumulation of knowledge remains constant. The evolution of pain management continues.

View original post here:
Home - Vermont Regenerative Medicine

The first patient in the landmark Pilot Investigation of Stem Cells in Stroke (PISCES) trial has been treated with neural stem cells. The study is the first fully regulated clinical trial of neural stem cell therapy for stroke. Investigators will evaluate the safety of ReNeuron cells in disabled ischemic stroke patients.

This is a first in man safety study, lead investigator Keith Muir, MD, from the University of Glasgows Institute of Neuroscience and Psychology in Scotland, explained to Medscape Medical News. We are looking at neurological effects clinical and imaging only as secondary goals.

The stem cells are from a genetically modified immortalized cell line derived from a tissue sample from 12-week fetal cortex.

Critics of stem cell development generally have various reasons for their ethical objections, Dr. Muir said. For most, it relates to embryo use not relevant in this case, he argues. Others might object to termination of pregnancy, but these cells are derived from material donated to a tissue bank from a single legal termination many years ago, which was done for social reasons and was unrelated to the subsequent use.

This study was approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency. ReNeuron is the first company to receive regulatory approval for any stem cellbased clinical trial in the United Kingdom.

PISCES Trial

The first patient in this pilot investigation was treated in Glasgow. The male patient was injected with cells to the affected region of the brain and has since been discharged from the hospital. He will be monitored closely for 2 years with longer-term follow-up procedures afterward.

Investigators are still recruiting for the trial and plan for 12 patients to take part. They will be given the ReN001 therapy between 6 and 24 months after stroke.

PISCES is an open-label study with no control group. We feel this is an appropriate design for a first in man study, Dr. Muir said, and we are not seeking to draw conclusions about efficacy at this stage.

Trial investigators suggest that because of the nature of the procedure and the characteristics of the stem cells, immunosuppression will not be necessary for patients taking part in the study. This, they say, will eliminate the safety risks typically associated with immunosuppression regimens.

Continue reading here:
First Stroke Patient Treated With Neural Stem Cell Therapy